the aid library

LIST OPTIONS

Filter

9508

Sort by:

Direction:

Download (1328)

View PDF (3216)

Infection Control Assessment Tool: A Standardized Approach for Improving Hospital Infection Control Practices

South Africa's Dept. of Health; USAID; SIAPS (2010) C1

The ICAT is a simple and practical approach for assessing the adequacy of existing infection prevention and control practices and provides specific recommendations for improving practices and monitoring their effectiveness over time

Download (171)

View PDF (268)

HEARTS. Technical package for cardiovascular disease management in primary health care. Evidence-based treatment protocols

World Health Organization WHO, et al. (2018) C_WHO

In many low- and middle-income countries, there is a wide gap between evidencebased recommendations and current practice. Treatment of major CVD risk factors remains suboptimal, and only a minority of patients who are treated reach their target levels for blood pressure, blood sugar and blood choles... more

Download (216)

View PDF (248)

Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in Primary Care

Ministry of Health and Consumer Affairs, Agencia Laín Entralgo. Unidad de Evaluación de Tecnologías Sanitaria, Madrid (2010) C2

The purpose of the Clinical Practice Guideline for Treatment of Patients with Anxiety Disorders in Primary Care is to provide professionals with practical recommendations based on scientific evidence to assist in the detection and effective treatment of these disorders

Download (274)

View PDF (436)

Executive summary: the selection and use of essential medicines 2021

World Health Organization WHO (2021) C_WHO

Report of the 23rd WHO Expert Committee on the selection and use of essential medicines This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)... more

Download (2833)

View PDF (1922)

WHO Guidelines for malaria
recommended

World Health Organization (WHO) (2022) C_WHO

25 Nov 2022 The WHO Guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform. The WHO Guidelines for malaria supersedes 2 previous WHO publications: the Guidelines for the treatment of mala... more

Download (621)

View PDF (349)

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

World Health Organization WHO (2022) C_WHO

The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ... more

Download (239)

View PDF (218)

Ensuring health security in the African region - Emergency preparedness and response flagship programmes

World Health Organization WHO, Regional Office of Africa (2022) C_WHO

The World Health Organization Regional Office for Africa (WHO AFRO), in accordance with recommendations from various WHO committees, has developed three flagship programmes to support Member States in the African region to prepare for, detect and respond to public health emergencies. They are the re... more

Download (106)

View PDF (135)

Practical manual on tuberculosis laboratory strengthening, 2022 update

World Health Organisation (WHO) (2023) C_WHO

The Practical manual on laboratory strengthening, 2022 update provides practical guidance on implementation of WHO recommendations and best practices for TB laboratory strengthening. It is an updated version of the GLI Practical Guide to Laboratory Strengthening published in 2017 and provides the la... more

Download (66)

View PDF (419)

WHO guideline on control and elimination of human schistosomiasis

World Health Organization WHO (2022) CC

Goal and objectives of the guideline The goal of this guideline is to provide evidence-based recommendations to countries in their efforts to accomplish schistosomiasis morbidity control and elimination as a public health problem, and to move towards interruption of transmission. The recommendatio... more

Download (137)

View PDF (163)

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

Download (106)

View PDF (126)

Ensuring health security in the African region: Emergency preparedness and response flagships progress report #4

World Health Organisation (WHO) (2022) C_WHO

The World Health Organization Regional Office for Africa (WHO AFRO), in accordance with recommendations from various WHO committees, has developed three flagship initiatives to support Member States in the African region to prepare for, detect and respond to public health emergencies. They are the r... more

Download (73)

View PDF (65)

Sustainable financing: feasibility of a replenishment mechanism, including options for consideration - Report by the Director-General

World Health Organization (WHO) World Health Organization (WHO) (2022) CC

The Seventy-fifth World Health Assembly through a decision on sustainable financing, adopted the recommendations of the Member States Working Group on Sustainable Financing, contained in Appendix 2 of the Working Group’s report to the Seventy-fifth World Health Assembly. As part of the recommendat... more

Download (240)

View PDF (323)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (10)

View PDF (8)

Sodium reduction

World Health Organization WHO (2023) C_WHO

Almost all populations are consuming too much sodium. The global mean intake of adults is 4310 mg/day sodium (equivalent to 10.78 g/day salt). This is more than double the World Health Organization recommendation for adults of less than 2000 mg/day sodium (equivalent to < 5 g/day salt). - The prima... more

Download (9)

View PDF (9)

ESC Clinical Practice Guidelines on Cardiovascular Disease Prevention in Clinical Practice: What Patients Need to Know

European Society of Cardiology (2022) CC

This guide for patients aims to provide you with an overview of the latest evidence-based recommendations for the prevention of cardiovascular disease. In particular, it should help you to understand: • how cardiovascular disease risk is assessed • the importance of lifestyle modifications for... more

Download (13)

View PDF (12)

South African cardiovascular risk stratification guideline for non-cardiac surgery

Alphonsus, C.; Naidoo, N.; Motshabi, P. et al. South African Medical Journal (2021) CC

The South African (SA) guidelines for cardiac patients for non-cardiac surgery were developed to address the need for cardiac risk assessment and risk stratification for elective non-cardiac surgical patients in SA, and more broadly in Africa. The guidelines were developed by updating the Canadian ...Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Non-cardiac Surgery, with a search of literature from African countries and recent publications. The updated proposed guidelines were then evaluated in a Delphi consensus process by SA anaesthesia and vascular surgical experts. The recommendations in these guidelines are: 1. We suggest that elective non-cardiac surgical patients who are 45 years and older with either a history of coronary artery disease, congestive cardiac failure, stroke or transient ischaemic attack, or vascular surgical patients 18 years or older with peripheral vascular disease require further preoperative risk stratification as their predicted 30-day major adverse cardiac event (MACE) risk exceeds 5% (conditional recommendation: moderate-quality evidence). 2. We do not recommend routine non-invasive testing for cardiovascular risk stratification prior to elective non-cardiac surgery in adults (strong recommendation: low-to-moderate-quality evidence). 3. We recommend that elective non-cardiac surgical patients who are 45 years and older with a history of coronary artery disease, or stroke or transient ischaemic attack, or congestive cardiac failure or vascular surgical patients 18 years or older with peripheral vascular disease should have preoperative natriuretic peptide (NP) screening (strong recommendation: high-quality evidence). 4. We recommend daily postoperative troponin measurements for 48 - 72 hours for non-cardiac surgical patients who are 45 years and older with a history of coronary artery disease, or stroke or transient ischaemic attack, or congestive cardiac failure or vascular surgical patients 18 years or older with peripheral vascular disease, i.e. (i) a baseline risk >5% for MACE 30 days after elective surgery (if no preoperative NP screening), or (ii) an elevated B-type natriuretic peptide (BNP)/N-terminal-prohormone B-type natriuretic peptide (NT-proBNP) measurement before elective surgery (defined as BNP >99 pg/mL or a NT-proBNP >300 pg/mL) (conditional recommendation: moderate-quality evidence). Additional recommendations are given for the management of myocardial injury after non-cardiac surgery (MINS) and medications for comorbidities. more

Download (3)

View PDF (4)

Development of WHO immunization policy and strategic guidance

World Health Organization WHO (2024) C_WHO

This guidance describes the methods and processes of the Strategic Advisory Group of Experts (SAGE) on Immunization in developing evidence-based recommendations, WHO vaccine position papers, and other immunization policy guidance. Its aim is to facilitate the work of SAGE, its working groups and the... more

Download (3)

View PDF (1)

Alcohol consumption and sustainable development: fact sheet on Sustainable Development Goals (‎SDGs)‎: health targets

World Health Organization WHO (2020) C_WHO

The Sustainable Development Goals (‎SDGs)‎ aim to transform our world. They are a call to action to end poverty and inequality, protect the planet, and ensure that all people enjoy health, justice and prosperity. It is critical that no one is left behind. In 2015, all the countries in the United... more

Download (68)

View PDF (76)

Microplanning Manual for Malaria Elimination in the Region of the Americas. Version for field personnel

World Health Organisation (WHO) (2024) C_WHO

The purpose of this manual is to provide guidance on how to implement Pan American Health Organization (PAHO) recommendations for malaria elimination at the local level. It is a streamlined, more operational version of the Manual for Stratifying Malaria Risk and Elimination of Foci, aimed primarily ... more

Download (10)

View PDF (12)

Summary of WHO infection prevention and control guideline for Ebola and Marburg disease: a call for evidence based practice

World Health Organisation (WHO) (2024) C_WHO

This article summarises the process involved in developing the updated guideline and includes an infographic to highlight key IPC recommendations from the guideline, following the patient care pathway from the community to a healthcare facility to discharge.

WHO Guidelines for malaria recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support recommended

WHO Guidelines for malaria
recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended